Influx Healthtech Ltd
Influx Healthtech Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #35 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Post-expansion, Influx Healthtech expects a 2.5x increase in capacity based on FY25 figures, aiming to reach approximately INR 500 crores in topline within 2.5 to 3 years (FY27-FY28 timeframe). The company expects a topline of INR 500 crores post a 2.5x capacity expansion, likely achieved in 2.5 to 3 years (FY27-FY28).
From Influx Healthtech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Post-expansion, Influx Healthtech expects a 2.5x increase in capacity based on FY25 figures, aiming to reach approximately INR 500 crores in topline within 2.5 to 3 years (FY27-FY28 timeframe).
- Annual revenue growth is expected to continue at a similar pace of 20%-25% with ongoing machinery installations and new product lines (beverage and pet food).
- The pet food segment will increase capacity by 10x, significantly boosting output.
- The beverage line, including carbonation and RTD (ready-to-drink) nutritional drinks, is anticipated to scale up gradually after successful pilot exports.
- The veterinary segment is projected to grow strongly over 5-10 years, potentially paralleling nutraceutical growth.
2 more points from Influx Healthtech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Influx Healthtech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex from IPO proceeds planned: approx. INR 20-23 Cr for nutraceuticals and INR 11 Cr for veterinary (FY26-FY27).
- By H1 FY27, most IPO funds expected to be utilized.
- Machinery orders include beverage line (10,000 bottles/hour), pet food line (1,000 kg/hour), and retort plant.
- Installation timelines: beverage and pet food machinery expected operational by January 2026; overall new factory operational by H1 FY26 (May-June 2026), delayed slightly due to rains.
- Internal accruals augmenting capacity expansion; about INR 11.7 Cr capex done by H1 FY26.
- Future plans to add innovative, automized machines after current expansion.
2 more points from Influx Healthtech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Influx Healthtech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Orders are robust across segments, with clients expanding and requiring increased capacity.
- There is ongoing export activity, including shipments to Caribbean Islands and African markets like Tanzania, Nigeria, and Kenya.
- The company is optimistic about scaling up production, especially with new machinery for beverage lines and pet food.
2 more points from Influx Healthtech Ltd's call on order book
Create a free account to keep reading this call
Continue your research
What Influx Health.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Influx Healthtech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Influx Healthtech Ltd Q2 FY26 results?
Post-expansion, Influx Healthtech expects a 2.5x increase in capacity based on FY25 figures, aiming to reach approximately INR 500 crores in topline within 2.5 to 3 years (FY27-FY28 timeframe). The company expects a topline of INR 500 crores post a 2.5x capacity expansion, likely achieved in 2.5 to 3 years (FY27-FY28).
What is Influx Healthtech Ltd share price analysis?
Influx Healthtech Ltd currently shows a neutral. The stock trades at a P/E of 33.5 with a market cap of ₹689 Cr. Investors should review the full earnings analysis for detailed insights.
Is Influx Healthtech Ltd planning capital expenditure?
Capex from IPO proceeds planned: approx.
Keep Influx Healthtech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.